The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy refractory advanced and metastatic biliary adenocarcinoma/cholangiocarcinoma.
 
Weijing Sun
Honoraria - Genentech/Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - Bayer; Merck (Inst)
 
Daniel Paul Normolle
No Relationships to Disclose
 
Nathan Bahary
Consulting or Advisory Role - Bayer/Onyx; EMD Serono
Research Funding - Newlink Genetics
 
James Ohr
No Relationships to Disclose
 
Barry C. Lembersky
Speakers' Bureau - Genentech
 
Krishna Patel
No Relationships to Disclose
 
Anuj K. Patel
No Relationships to Disclose
 
James J. Lee
Consulting or Advisory Role - Genentech
Research Funding - Merck
 
Edward Chu
No Relationships to Disclose
 
Natalie Streeter
No Relationships to Disclose
 
Summer Drummond
No Relationships to Disclose
 
John P. Morcos
No Relationships to Disclose
 
Matthew Gerard Sulecki
No Relationships to Disclose
 
David A. Geller
No Relationships to Disclose
 
J. Wallis Marsh
No Relationships to Disclose
 
Allan Tsung
No Relationships to Disclose
 
Herbert Zeh
Research Funding - Aduro Biotech (Inst)